izpis_h1_title_alt

DPP-4 inhibitors in the prevention/treatment of pulmonary fibrosis, heart and kidney injury caused by covid-19-a therapeutic approach of choice in type 2 diabetic patients?
ID Smelcerović, Andrija (Avtor), ID Kocic, Gordana (Avtor), ID Gajic, Mihajlo (Avtor), ID Tomović, Katarina (Avtor), ID Djordjevic, Vukica (Avtor), ID Stankovic-Djordjevic, Dobrila (Avtor), ID Anderluh, Marko (Avtor)

.pdfPDF - Predstavitvena datoteka, prenos (375,34 KB)
MD5: 4E03EF535C418AF8D53F5B92F32A6D72
URLURL - Izvorni URL, za dostop obiščite https://www.frontiersin.org/articles/10.3389/fphar.2020.01185/full Povezava se odpre v novem oknu

Izvleček
Since the outbreak of SARS-CoV-2 virus more than 12,500,000 cases have been reported worldwide. Patients suffering from diabetes and other comorbidities are particularly susceptible to severe forms of the COVID-19, which might result in chronic complications following recovery. Dipeptidyl peptidase-4 inhibitors exert beneficial effects in prevention/treatment of pulmonary fibrosis, heart, and kidney injury, and since they may be a long-term consequence caused by COVID-19, it is reasonable to expect that DPP-4 inhibitors might be beneficial in alleviating long-term consequences of COVID-19. With that in mind, we would like to voice our concerns over chronic implications following recovery from COVID-19, especially not only in diabetic but also in non-diabetic patients, and to indicate that some preventive measures could be undertaken by application of DPP-4 inhibitors.

Jezik:Angleški jezik
Ključne besede:COVID-19, diabetes, DPP-4 inhibitors, fibrosis, multi-organ injury
Vrsta gradiva:Članek v reviji
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:FFA - Fakulteta za farmacijo
Status publikacije:Objavljeno
Različica publikacije:Objavljena publikacija
Leto izida:2020
Št. strani:4 str.
Številčenje:Vol. 11, art. 1185
PID:20.500.12556/RUL-124557 Povezava se odpre v novem oknu
UDK:616.9+616.2
ISSN pri članku:1663-9812
DOI:10.3389/fphar.2020.01185 Povezava se odpre v novem oknu
COBISS.SI-ID:25125123 Povezava se odpre v novem oknu
Datum objave v RUL:02.02.2021
Število ogledov:987
Število prenosov:289
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Gradivo je del revije

Naslov:Frontiers in pharmacology
Skrajšan naslov:Front Pharmacol
Založnik:Frontiers Media
ISSN:1663-9812
COBISS.SI-ID:29551833 Povezava se odpre v novem oknu

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:02.02.2021

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:COVID-19, poškodbe notranjih organov, korona virus, DPP-4 zaviralci, pljučna fibroza

Projekti

Financer:MESTD - Ministry of Education, Science and Technological Development of Republic of Serbia

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Serbian Academy of Sciences and Arts, Niš
Številka projekta:О-06-17

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Faculty of Medicine of the University of Niš
Številka projekta:internal project no. 40

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:P1-0208
Naslov:Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj